CL2019003789A1 - Tratamiento con plasminógeno de afecciones asociadas a la sobreexpresión de pai-1. - Google Patents
Tratamiento con plasminógeno de afecciones asociadas a la sobreexpresión de pai-1.Info
- Publication number
- CL2019003789A1 CL2019003789A1 CL2019003789A CL2019003789A CL2019003789A1 CL 2019003789 A1 CL2019003789 A1 CL 2019003789A1 CL 2019003789 A CL2019003789 A CL 2019003789A CL 2019003789 A CL2019003789 A CL 2019003789A CL 2019003789 A1 CL2019003789 A1 CL 2019003789A1
- Authority
- CL
- Chile
- Prior art keywords
- pai
- overexpression
- conditions associated
- plasminogen
- treatment
- Prior art date
Links
- 102000013566 Plasminogen Human genes 0.000 title abstract 3
- 108010051456 Plasminogen Proteins 0.000 title abstract 3
- 230000002018 overexpression Effects 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 201000010099 disease Diseases 0.000 abstract 3
- 102000012335 Plasminogen Activator Inhibitor 1 Human genes 0.000 abstract 2
- 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 abstract 2
- 208000032594 Vascular Remodeling Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002503 metabolic effect Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/484—Plasmin (3.4.21.7)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Pulmonology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762523901P | 2017-06-23 | 2017-06-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2019003789A1 true CL2019003789A1 (es) | 2020-07-10 |
Family
ID=64737041
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2019003789A CL2019003789A1 (es) | 2017-06-23 | 2019-12-20 | Tratamiento con plasminógeno de afecciones asociadas a la sobreexpresión de pai-1. |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US11826404B2 (enExample) |
| EP (1) | EP3641888B1 (enExample) |
| JP (1) | JP2020524689A (enExample) |
| KR (1) | KR20200019217A (enExample) |
| CN (1) | CN110831668B (enExample) |
| AU (1) | AU2018287316B2 (enExample) |
| BR (1) | BR112019027229A2 (enExample) |
| CA (1) | CA3068153A1 (enExample) |
| CL (1) | CL2019003789A1 (enExample) |
| DK (1) | DK3641888T3 (enExample) |
| ES (1) | ES2965937T3 (enExample) |
| FI (1) | FI3641888T3 (enExample) |
| IL (1) | IL271470B2 (enExample) |
| MX (1) | MX2019015741A (enExample) |
| MY (1) | MY203136A (enExample) |
| RU (1) | RU2020100080A (enExample) |
| SG (1) | SG11201912813SA (enExample) |
| TW (1) | TWI868051B (enExample) |
| WO (1) | WO2018234861A1 (enExample) |
| ZA (1) | ZA202000280B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018108161A1 (zh) | 2016-12-15 | 2018-06-21 | 深圳瑞健生命科学研究院有限公司 | 一种预防和治疗肥胖症的方法和药物 |
| US11389515B2 (en) | 2016-12-15 | 2022-07-19 | Talengen International Limited | Method for mitigating heart disease |
| TW201822809A (zh) | 2016-12-15 | 2018-07-01 | 深圳瑞健生命科學硏究院有限公司 | 一種預防和治療高脂血症的方法 |
| EP4094775A4 (en) * | 2020-02-06 | 2023-04-19 | Talengen International Limited | METHODS AND MEDICATIONS FOR THE PREVENTION AND TREATMENT OF MULTIPLE SCLEROSIS |
| JP2023518563A (ja) * | 2020-03-24 | 2023-05-02 | タレンゲン インターナショナル リミテッド | パーキンソン病を治療する方法及び薬剤 |
| TW202143999A (zh) * | 2020-03-24 | 2021-12-01 | 大陸商深圳瑞健生命科學研究院有限公司 | 一種促進錯誤摺疊蛋白及其聚集物降解的方法和藥物 |
| WO2021190558A1 (zh) * | 2020-03-24 | 2021-09-30 | 泰伦基国际有限公司 | 一种治疗阿尔茨海默病的方法和药物 |
| CN112174979B (zh) * | 2020-10-27 | 2021-09-07 | 黑龙江中医药大学 | 一种治疗多囊卵巢综合征的药物及其制备方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5520912A (en) | 1993-07-02 | 1996-05-28 | Immuno Aktiengesellschaft | Prevention and treatment of ischemic events and reperfusion injury resulting therefrom using lys-plasminogen |
| US6677473B1 (en) * | 1999-11-19 | 2004-01-13 | Corvas International Inc | Plasminogen activator inhibitor antagonists |
| AU3173301A (en) * | 2000-02-11 | 2001-08-20 | European Molecular Biology Laboratory | Methods and compositions for treatment of alzheimer's disease by enhancing plasmin or plasmin-like activity |
| GB0509438D0 (en) | 2005-05-09 | 2005-06-15 | Prometic Biosciences Ltd | Affinity adsorbets for fibrinogen |
| EP2056865B1 (en) * | 2006-08-28 | 2013-12-25 | Omnio Healer AB | Novel drug target of preventing and treating periodontal disease, improving healing of periodontal wounds and promoting oral health |
| CN101573134B (zh) * | 2006-08-28 | 2013-03-06 | 李季男 | 抗感染候选药物 |
| EA033403B1 (ru) * | 2013-08-13 | 2019-10-31 | Sanofi Sa | Антитела к ингибитору активатора плазминогена 1 (pai-1) и пути их применения |
| TWI801331B (zh) * | 2015-11-03 | 2023-05-11 | 美商波麥堤克生物治療股份有限公司 | 纖維蛋白溶酶原缺乏症之纖維蛋白溶酶原替代療法 |
| TW201722464A (zh) * | 2015-11-10 | 2017-07-01 | 波麥堤克生化科學有限公司 | 用於傷口癒合之纖維蛋白溶酶原給藥方案 |
| WO2018108161A1 (zh) * | 2016-12-15 | 2018-06-21 | 深圳瑞健生命科学研究院有限公司 | 一种预防和治疗肥胖症的方法和药物 |
| EP3556380A4 (en) * | 2016-12-15 | 2020-05-13 | Talengen International Limited | METHOD FOR PREVENTING AND TREATING FABRIC OF TISSUE AND ORGAN |
| CA3047170A1 (en) * | 2016-12-15 | 2018-06-21 | Talengen International Limited | Method for preventing and treating drug-induced renal injury |
-
2018
- 2018-06-15 TW TW107120839A patent/TWI868051B/zh active
- 2018-06-22 MY MYPI2019007619A patent/MY203136A/en unknown
- 2018-06-22 US US16/625,335 patent/US11826404B2/en active Active
- 2018-06-22 AU AU2018287316A patent/AU2018287316B2/en active Active
- 2018-06-22 DK DK18821458.9T patent/DK3641888T3/da active
- 2018-06-22 IL IL271470A patent/IL271470B2/en unknown
- 2018-06-22 ES ES18821458T patent/ES2965937T3/es active Active
- 2018-06-22 FI FIEP18821458.9T patent/FI3641888T3/fi active
- 2018-06-22 MX MX2019015741A patent/MX2019015741A/es unknown
- 2018-06-22 WO PCT/IB2018/000655 patent/WO2018234861A1/en not_active Ceased
- 2018-06-22 KR KR1020207001617A patent/KR20200019217A/ko not_active Ceased
- 2018-06-22 JP JP2019570806A patent/JP2020524689A/ja active Pending
- 2018-06-22 BR BR112019027229-1A patent/BR112019027229A2/pt not_active Application Discontinuation
- 2018-06-22 RU RU2020100080A patent/RU2020100080A/ru unknown
- 2018-06-22 CN CN201880041573.5A patent/CN110831668B/zh active Active
- 2018-06-22 CA CA3068153A patent/CA3068153A1/en active Pending
- 2018-06-22 SG SG11201912813SA patent/SG11201912813SA/en unknown
- 2018-06-22 EP EP18821458.9A patent/EP3641888B1/en active Active
-
2019
- 2019-12-20 CL CL2019003789A patent/CL2019003789A1/es unknown
-
2020
- 2020-01-15 ZA ZA2020/00280A patent/ZA202000280B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN110831668A (zh) | 2020-02-21 |
| WO2018234861A1 (en) | 2018-12-27 |
| EP3641888B1 (en) | 2023-10-11 |
| KR20200019217A (ko) | 2020-02-21 |
| IL271470B2 (en) | 2025-07-01 |
| MY203136A (en) | 2024-06-10 |
| RU2020100080A (ru) | 2021-07-23 |
| SG11201912813SA (en) | 2020-01-30 |
| DK3641888T3 (da) | 2024-01-02 |
| AU2018287316B2 (en) | 2024-09-19 |
| TWI868051B (zh) | 2025-01-01 |
| FI3641888T3 (fi) | 2023-12-19 |
| US11826404B2 (en) | 2023-11-28 |
| BR112019027229A2 (pt) | 2020-07-07 |
| IL271470B1 (en) | 2025-03-01 |
| CN110831668B (zh) | 2024-04-12 |
| RU2020100080A3 (enExample) | 2021-11-02 |
| MX2019015741A (es) | 2020-11-11 |
| ES2965937T3 (es) | 2024-04-17 |
| JP2020524689A (ja) | 2020-08-20 |
| TW201904990A (zh) | 2019-02-01 |
| ZA202000280B (en) | 2021-08-25 |
| CA3068153A1 (en) | 2018-12-27 |
| IL271470A (en) | 2020-01-30 |
| US20210330761A1 (en) | 2021-10-28 |
| AU2018287316A1 (en) | 2020-02-06 |
| EP3641888A1 (en) | 2020-04-29 |
| EP3641888A4 (en) | 2021-03-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2019003789A1 (es) | Tratamiento con plasminógeno de afecciones asociadas a la sobreexpresión de pai-1. | |
| IL280710A (en) | Methods and compositions for treating mitochondrial disease or disorders and heteroplasmy | |
| MX2022007989A (es) | Composiciones y metodos para tratar pterigion. | |
| PL3673080T3 (pl) | Oligomery antysensowne do leczenia stanów i chorób | |
| CY1120950T1 (el) | Θεραπεια ινωσης | |
| IL268850A (en) | Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases | |
| CO2017004715A2 (es) | Métodos y formulaciones para tratar enfermedades vasculares de los ojos | |
| BR112018005114A2 (pt) | um novo polipeptídeo de endolisina | |
| MX2018008557A (es) | Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismos. | |
| MX2017014645A (es) | Profarmacos de alvocidib que tienen una biodisponibilidad aumentada. | |
| EA201692436A1 (ru) | Медицинское применение | |
| MX2022007436A (es) | Inhibidores de la autotaxina y sus usos. | |
| MX2021006408A (es) | Terapia de combinacion de radioinmunoconjugados con inhibidores de da?os y reparaciones del adn. | |
| EA201691320A1 (ru) | Способы лечения пациентов с гиперхолестеринемией, которая устойчива к терапии умеренными дозами статинов | |
| MX2022004143A (es) | Compuesto que tiene actividad inhibidora de brd4, su método de preparación y su uso. | |
| AR115583A1 (es) | Composiciones y métodos para el tratamiento de las enfermedades y trastornos del hígado | |
| CR20190471A (es) | Moduladores de la expresión de pcsk9 | |
| JOP20210050A1 (ar) | معدلات تعبير pnpla3 | |
| IL272601A (en) | Pharmaceutical compositions for the treatment of ophthalmic conditions | |
| MX2020004666A (es) | Compuestos de pilocarpina con ácido lipoico para el tratamiento de trastornos oculares. | |
| IL286268A (en) | Pridopidine for use in the treatment of mitochondrial associated diseases and disorders, including symptoms thereof | |
| EA201892265A1 (ru) | Способы лечения офтальмологических заболеваний | |
| IL287704A (en) | Use of cannabidiol in the treatment of tuberous sclerosis complex | |
| MX387839B (es) | Laminina para usarse en el tratamiento de una enfermedad, un trastorno o una afección de un endotelio de córnea. | |
| EA201790893A1 (ru) | Способы лечения офтальмологических расстройств |